MedPlus subsidiary, Optival Health Solutions Private Limited, has been issued three separate suspension orders for the Drug Licenses of three retail stores across Karnataka, Telangana, and Andhra Pradesh. The suspensions range from two to seven days and were issued by local Drug Control Administrations. The company has assessed the potential financial impact, estimating a cumulative Revenue Loss of Rs 4.81 lacs across the affected locations due to these temporary operational halts.
Regulatory Action Against Subsidiary Stores
MedPlus Health Services Limited has disclosed that its subsidiary, Optival Health Solutions Private Limited, has received orders suspending the Drug Licenses for three of its retail outlets located in Southern and Central India. These actions, stemming from alleged contraventions of the Drugs and Cosmetics Act, resulted in temporary store closures.
Summary of Suspension Orders
The announcement details three distinct regulatory actions taken by local authorities:
- Karnataka Store (Ramanagar): A suspension order for two days was received on 13.03.2026 for the store at Kempegowda Circle. This resulted in a potential revenue loss estimated at Rs 1.07 lacs.
- Telangana Store (Rangareddy): The store at Dilsukhnagar Alkapuri faces a suspension for three days. The applicable rules cited were Rule 65 of the Drugs and Cosmetics Act, 1940, leading to an estimated revenue loss of Rs 1.60 lacs.
- Andhra Pradesh Store (Krishna & NTR Districts): This location faces the longest suspension of seven days for the store situated at Penuganchiprolu Main Road. The projected financial impact is a potential revenue loss of Rs 2.12 lacs.
Financial Implication Assessment
The company has quantified the financial impact based on the duration and location of the mandated store closures. The total quantifiable potential revenue loss across all three incidents is calculated to be approximately Rs 4.81 lacs (1.07 + 1.60 + 2.12 lacs). The management confirms that these operational disruptions are detailed in official communications received by the company on or around March 13, 2026.
Source: BSE
